Public Offerings of Common Stock, Financial Results, and Significant Progress in Key Development Programs - Research Report on

Public Offerings of Common Stock, Financial Results, and Significant Progress
 in Key Development Programs - Research Report on BioCryst, Exelixis, Idenix,
                       Puma Biotechnology, and Halozyme

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, August 12, 2013

NEW YORK, August 12, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting BioCryst
Pharmaceuticals, Inc. (NASDAQ: BCRX), Exelixis, Inc. (NASDAQ: EXEL), Idenix
Pharmaceuticals, Inc. (NASDAQ: IDIX), Puma Biotechnology, Inc. (NYSE: PBYI),
and Halozyme Therapeutics, Inc. (NASDAQ: HALO). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

BioCryst Pharmaceuticals, Inc. Research Report

On August 5, 2013, BioCryst Pharmaceuticals, Inc. (BioCryst) announced that
underwriters of the Company's recent public offering of its common stock have
fully exercised their option to purchase additional 600,000 shares. The
Company expects $20.2 million of total gross proceeds from the offering to
BioCryst, which includes proceeds from the exercise of the over-allotment
option. BioCryst stated that the offering, including the sale of additional
shares will close on August 6, 2013 subject to customary closing conditions
and it intends to use net proceeds of the same towards second generation
hereditary angioedema compounds and pre commercialization activities related
to intravenous peramivir. The Full Research Report on BioCryst
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/f9b1_BCRX]

--

Exelixis, Inc. Research Report

On August 6, 2013, Exelixis, Inc. (Exelixis) reported Q2 2013 financial
results. The Company generated net revenues of $11.9 million, up 51.7% YoY.
According to Exelixis, the increase was due to $4 million of net product
revenue resulting from the sale of COMETRIQ. Net loss was $62.2 million, or
$0.34 per basic share, compared with $36.5 million, or $0.25 per basic share,
in Q2 2012. Michael M. Morrissey, Ph.D., President and CEO of Exelixis said,
"While continuing to focus on enrollment of the COMET phase 3 pivotal trials
as our top priority, we initiated the METEOR phase 3 pivotal trial in
metastatic hepatocellular carcinoma (HCC). In addition, the overall survival
and post-hoc analyses from the phase 2 NRE metastatic CRPC cohort were
presented at the ASCO Annual Meeting and those data continue to support the
rationale for the COMET pivotal trials in metastatic CRPC, for which we
continue to expect top-line data in 2014." The Full Research Report on
Exelixis, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/73be_EXEL]

--

Idenix Pharmaceuticals, Inc. Research Report

On August 7, 2013, Idenix Pharmaceuticals, Inc. (Idenix) reported Q2 2013
financial results with total revenues of $0.1 million, down 92.2% YoY. Q2 2013
net loss was $28.9 million, or $0.22 per basic share, compared with $25.4
million, or $0.23 per basic share, in Q2 2012. Ron Renaud, President and CEO
of Idenix said, "In the second quarter, we saw significant progress of our
lead HCV development program, samatasvir, and continue to be on track to
report data from the first patient cohort in the fourth quarter of this year.
We remain committed to our HCV nucleotide franchise, and we are actively
pursuing additional paths forward with the ultimate goal remaining the
evaluation of an all-oral internally developed pan-genotypic combination
regimen including samatasvir and a nucleotide inhibitor." The Full Research
Report on Idenix Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/c979_IDIX]

--

Puma Biotechnology, Inc. Research Report

On August 6, 2013, Puma Biotechnology, Inc. (Puma Biotechnology) reported Q2
2013 financial results. The Company reported Q2 2013 net loss applicable to
common stock of $12.6 million, or $0.44 per share, compared with a net loss of
$14.8 million, or $0.74 per share, in Q2 2012. Alan H. Auerbach, CEO and
President of Puma Biotechnology said, "During the second quarter of 2013, we
achieved an important clinical milestone for PB272 with the initiation of our
Phase III trial in patients with HER2-positive metastatic breast cancer who
have failed two or more prior treatments. We look forward to aggressively
recruiting for this trial during the remainder of this year and first half of
next year." The Full Research Report on Puma Biotechnology, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/4d27_PBYI]

--

Halozyme Therapeutics, Inc. Research Report

On August 7, 2013, Halozyme Therapeutics, Inc. (Halozyme) reported Q2 2013
financial results with total revenues of $14.5 million, up 86.3% YoY. Net loss
for Q2 2013 was $22.9 million, or $0.20 per share, compared with $14 million,
or $0.13 per share, in Q2 2012. Gregory I. Frost, Ph.D., President and CEO of
Halozyme said, "Significant regulatory milestones were achieved with Baxter's
HyQvia and Roche's Herceptin last quarter. Working with our partners, we look
forward to bringing these life-changing treatments to patients and medical
communities across Europe." The Full Research Report on Halozyme Therapeutics,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/ea1b_HALO]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.